In order to access this content you must be logged in and have a subscription to PL Intelligence.

PL Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
OXiGENE signs Letter of Intent with Bristol-Myers Squibb
BRISTOL-MYERS SQUIBB TO ACQUIRE ADNEXUS THERAPEUTICS
Elan and Bristol-Myers Squibb sign license agreement
Bristol-Myers Squibb Proposes to Acquire ImClone Systems for $60.00 Per Share in Cash
Bristol-Myers Squibb Announces Completion of ConvaTec Divestiture